Last reviewed · How we verify
MRX2843
At a glance
| Generic name | MRX2843 |
|---|---|
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors (PHASE1)
- Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL (PHASE1)
- MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer (PHASE1)
- A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MRX2843 CI brief — competitive landscape report
- MRX2843 updates RSS · CI watch RSS
- Betta Pharmaceuticals Co., Ltd. portfolio CI